This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Santa Ana, CA

Saint Joseph, MO

Derm Center

Fort Smith, AR

Arlington, TX

Texas Medical Center

Novartis

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country.

The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to \<18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Warsaw, Poland

Benowa, Australia

Krakow, Poland

Wroclaw, Poland

Maroubra

Edmonton, AB

Portland, OR

Calgary, Canada

Carlton, Australia

East Melbourne, Australia

Spokane, WA

Sheffield Children's Hospital - Clinical Research Facility

Luigi Sacco University Hospital - Gastroenterology and Digestive Endoscopy Department

Santa Monica, CA

Rapid City, SD

Fountain Valley, CA

HQ, Irvine, CA

Encinitas, CA

San Diego, CA

Minneapolis, MN

Sudbury, Canada

Clinical Research Unit

Clinique Medicale Saint-Louis

Barrie, Canada

St. Johns, NL

Clinical Operations Department

Clarkston, MI

Richmond Hill, Canada

Ontario, CA

Ontario, Canada

Normal, IL

Troy, MI

Toronto, Canada

Mississauga, Canada

London, Canada

Oakvile, Canada

Windsor, Canada

UR Dermatology at College Town

Indianapolis, IN

Plainfield, IN

Bexley, OH

Owensboro, KY

Forest Hills Dermatology Group

White Marsh, MD

Rockville, MD

Pflugerville, TX

San Antonio, TX

San Antonio, Texas

Greensboro - Cardiology

Shelby, NC

Norfolk, VA

Monterrey, Mexico

Jacksonville, FL

JM Research SC

Tampa, FL

Veracruz, Mexico

Boca Raton, FL

Miami Lakes, FL

Miami, FL

Clinical Research Site

Merida, Mexico

Pfizer

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Nagoya City University Hospital

Tartu, Estonia

Szolnok, Hungary

Kelowna, Canada

Hannover, Germany

Vida Dermatology South

 Edmonton, Canada

Clinical Trial Center

Remscheid, Germany

Clinical Research Institute of Southern Oregon (CRISOR)

Maldegem, Belgium

Saskatoon, Canada

Haematology Department

Boise, ID

Sacramento, CA

Dublin, CA

Reno - Moana Lane Location

Bakersfield, CA

Canoga Park, California

Northridge, CA

Los Angeles, CA

Long Beach, CA

Las Vegas, NV

Scottsdale, AZ

Albuquerque, NM

Lincoln, NE

Dermatology and Skin Cancer Center Leawood

Ottawa, Canada

Newmarket, Canada

Waterloo, Canada

Burlington, Canada

Hamilton, Canada

Niagara Falls, Canada

West Lafayette, Indiana

Oklahoma City, OK

SLUCare Academic Pavilion - Endocrinology Division Research

Plano, TX

Department of Cardiology

Hot Springs, AR

North Little Rock

Camp Hill, PA

Jose Garcia, Coordinator

New York, NY

Towson, MD

Chevy Chase, MD

Bellaire, TX

McGovern Medical School - ACTAT - Research Department

Internal Medicine Glennan Center for Geriatrics and Gerontology

Charlotte, NC

Research Center

Hialeah, FL

Coral Gables, FL

San Juan, PR

Santiago, Chile

Buenos Aires, Argentina

Amgen

A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis.

The aim of this study is to evaluate the safety and efficacy of ADSTEM Inj. against Placebo in the treatment of atopic dermatitis in patients with moderate to severe acute and chronic atopic.

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

EHL Bio

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

 Thousand Oaks, CA

Quincy, MA

Dallas, TX

Plymouth Meeting, PA

Austin, TX

Cypress, TX

Dawsonville, GA

Coral Springs - Oncology

Margate, FL

AbbVie

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma

Find clinical trials for Eczema in Hanyang, Seoul

Related conditions:

Eczema trials near Hanyang, Seoul, KOR:

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Hanyang, Seoul

Related conditions:

Eczema trials near Hanyang, Seoul, KOR:

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in Hanyang, Seoul